Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

CJC-1295 - No DAC 10MG

CJC-1295 No DAC

CJC-1295 No DAC, also known as MOD-GRF (1-29), is a synthetic peptide analog of endogenous growth hormone–releasing hormone (GHRH), engineered for use as a research compound in studies of growth hormone signaling and hypothalamic–pituitary axis regulation. Unlike CJC-1295 with DAC, this variant lacks the drug affinity complex, resulting in a shorter biological half-life and a signaling profile that more closely mimics natural pulsatile GHRH release.*

In laboratory research settings, CJC-1295 No DAC is utilized to investigate GHRH receptor activation, growth hormone pulse dynamics, and peptide-mediated endocrine signaling under controlled experimental conditions. Its structural similarity to native GHRH (1-29) makes it a valuable tool for mechanistic and comparative research involving growth hormone regulation.*

Key Specifications

  • Peptide Name: CJC-1295 No DAC (MOD-GRF 1-29)
  • Peptide Class: Growth hormone–releasing hormone (GHRH) analog
  • Amino Acid Length: 29 amino acids
  • Form: Lyophilized powder
  • Purity: ≥99% (HPLC verified)
  • Quantity: 10 mg per vial
  • Analytical Verification: HPLC and Mass Spectrometry (MS)
  • Manufacturing: Solid-phase peptide synthesis with in-house purification
  • Designation: For Research Use Only (RUO)

$75.00

$71.25 each
$67.50 each

Products will arrive in a lyophilized (powder) form for maximum stability.

Free domestic shipping on orders over $300

CJC-1295 No DAC

Scientific & Research Context

CJC-1295 No DAC has been examined in scientific literature as a selective GHRH receptor agonist that stimulates endogenous growth hormone release without directly activating ghrelin receptors.* Research models frequently utilize this peptide to explore physiological growth hormone pulsatility, feedback regulation, and interactions between GHRH signaling and downstream insulin-like growth factor (IGF-1) pathways.*

Within experimental frameworks, CJC-1295 No DAC has been utilized to investigate:*

  • Growth hormone secretion patterns and pulse amplitude*
  • GHRH receptor binding and signal transduction mechanisms*
  • Endocrine feedback regulation within the hypothalamic–pituitary axis*
  • Comparative analysis of short-acting versus long-acting GHRH analogs*
  • Synergistic signaling interactions between GHRH analogs and growth hormone secretagogues*

Its short half-life and rapid clearance make CJC-1295 No DAC particularly useful for studies requiring precise temporal control of growth hormone release and receptor activation.*

Quality & Analytical Assurance

Each batch of CJC-1295 No DAC is manufactured using validated solid-phase peptide synthesis techniques and subjected to rigorous analytical testing. Verification by high-performance liquid chromatography (HPLC) and mass spectrometry (MS) confirms molecular identity, sequence accuracy, and purity, ensuring consistency and reproducibility across research applications.

Storage & Handling

CJC-1295 No DAC is supplied in lyophilized form to maintain stability during storage and transport. Store unopened vials in a cool, dry environment protected from light. Reconstitution and handling should follow established laboratory peptide protocols to preserve molecular integrity and minimize degradation.

For further information on proper storage techniques, click the button…

Storage Instructions

Referenced Scientific Literature
Provided for informational and educational purposes only

  • Jetté, L., et al. “Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog.” Endocrinology, vol. 146, no. 7, pp. 3052–3058, 2005.
  • Frohman, L. A., et al. “Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH₂ terminus.” Journal of Clinical Investigation, vol. 78, no. 4, pp. 906–913, 1986.
  • Izdebski, J., et al. “New potent hGH-RH analogues with increased resistance to enzymatic degradation.” Journal of Peptide Science, vol. 8, no. 7, pp. 289–296, 2002.
  • Alba, M., et al. “Once-daily administration of CJC-1295, a long-acting growth hormone–releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.” American Journal of Physiology – Endocrinology and Metabolism, vol. 291, no. 6, pp. E1290–E1294, 2006.
  • Ionescu, M., and Frohman, L. A. “Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a growth hormone–releasing hormone analog.” Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 12, pp. 4792–4797, 2006.
  • Smith, R. G., et al. “Development of growth hormone secretagogues.” Endocrine Reviews, vol. 18, no. 5, pp. 621–645, 1997.
  • Bowers, C. Y. “Growth hormone-releasing peptides: discovery, characterization and applications.” Endocrine Reviews, vol. 12, no. 3, pp. 334–357, 1991.
  • Van Hout, M. C., and Hearne, E. “Netnography of female use of the synthetic growth hormone CJC-1295.” Substance Use & Misuse, vol. 51, no. 1, pp. 73–84, 2016.
  • Frohman, L. A., and Ionescu, M. “Growth hormone secretion: physiological regulation and pharmacologic manipulation.” Endocrine, vol. 24, no. 1, pp. 11–18, 2004.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.